HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McNeil Aflexa

This article was originally published in The Tan Sheet

Executive Summary

"Do what moves you" is the tagline for nationwide TV and print effort for McNeil Consumer Healthcare's glucosamine 340 mg joint care supplement, the company announces May 18. Actress Esther Williams and musician Chubby Checker star in TV spots debuting May 22, while Williams and baseball player Hank Aaron are featured in print ads. The campaign will target women age 50 and older, the Fort Washington, Pa.-based J&J subsidiary says. Aflexa three-a-day tablets, which shipped in April to food, drug, mass and club outlets, are available in a 50-count bottle for $11.99 and 110-counts for $22.99; a 250-count bottle is available only in club stores. The full launch was preceded by test marketing in Florida (1"The Tan Sheet" Feb. 21, p. 3)

You may also be interested in...



J&J Supplement Offerings Grow With McNeil Aflexa Launch

Johnson & Johnson is adding to its portfolio of dietary supplements and functional foods with the introduction of McNeil Consumer Healthcare's Aflexa glucosamine dietary supplement in Florida.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel